Advanced urethral carcinomas: A retrospective analysis of survival outcomes and the role of cisplatin-based chemotherapy—The M. D. Anderson experience.

2012 ◽  
Vol 30 (5_suppl) ◽  
pp. 330-330
Author(s):  
Farshid Dayyani ◽  
Curtis A. Pettaway ◽  
Ashish M. Kamat ◽  
Mark F. Munsell ◽  
Lance C. Pagliaro
Keyword(s):  
Lymph Node ◽  
Locally Advanced ◽  
Neoadjuvant Treatment ◽  
Disease Free Survival ◽  
Retrospective Chart Review ◽  
Cancer Center ◽  
Treatment Standards ◽  
Node Positive ◽  
Response To Chemotherapy ◽  
Lymph Node Positive

330 Background: Primary carcinomas of the urethra (PCU) are rare and often advanced when diagnosed. Given the low incidence of this disease, there is a paucity of data regarding treatment standards. The purpose of this report was to study the treatment response and survival in a relatively large cohort of patients with PCU, with emphasis on modern platinum-containing chemotherapy regimens, in combination with surgery for (locally) advanced PCU. Methods: We performed a retrospective chart review of consecutive patients with PCU seen at the MD Anderson Cancer Center over a recent 5-year period (2005-2010). Clinical outcome was measured as best response to chemotherapy (either neo-adjuvant or for metastatic disease). Kaplan-Meier estimates were generated for survival and Cox proportional hazard was used for prognostic factors for survival. Results: We identified 44 consecutive pts with PCU. The majority (64%) were female, and the median age at diagnosis was 66.5 yrs. Squamous cell carcinoma and adenocarcinoma were the most common histologic subtypes of PCU in our cohort. 43% and 16% presented with lymph node–positive (LN+) and distant metastases, respectively. For all evaluable pts, the overall survival (OS) was 31.7 mo. Platinum-containing neoadjuvant chemotherapy achieved a response rate of 72%. 21/44 pts had locally advanced or LN+ PCU and were treated with chemotherapy followed by surgery. In this cohort, the median OS from chemotherapy initiation was 25.6 months. Among pts with LN+ PCU at diagnosis, 4/9 (44%) were alive as of July 2011, with a minimum follow-up of >3 years. Conclusions: We report the clinical outcomes in the to the best of our knowledge largest cohort of consecutive pts with PCU. Our data suggests that modern platinum-containing regimens are effective in a subset of advanced PCU. Neoadjuvant treatment leads to prolonged disease-free survival in a substantial proportion of lymph node positive cases.

Outcome of patients with clinically node-positive bladder cancer who undergo consolidative surgery after preoperative chemotherapy: MD Anderson Cancer Center experience.

2014 ◽  
Vol 32 (4_suppl) ◽  
pp. 318-318
Author(s):  
Philip Levy Ho ◽  
Daniel Levi Willis ◽  
Jeevitha Patil ◽  
Karen Tart ◽  
Sahil Parikh ◽  
...  
Keyword(s):  
Bladder Cancer ◽  
Lymph Node ◽  
Median Survival ◽  
Preoperative Chemotherapy ◽  
Clinical Evidence ◽  
Disease Free Survival ◽  
Cancer Center ◽  
Node Positive ◽  
Response To Chemotherapy ◽  
Clinically Node Positive

318 Background: We previously reported results of our phase II study in patients with retroperitoneal lymph node (RPLN) metastasis from bladder cancer (BC) undergoing consolidative surgery after preoperative chemotherapy. Here we present an expanded cohort of patients who underwent consolidative surgery after chemotherapy for clinically node-positive BC. Methods: We reviewed results of patients from our IRB approved protocol including those with clinical evidence of nodal metastasis in the pelvis or retroperitoneum (M1), without visceral metastasis, from 1995-2010. Endpoint of the study was cancer-specific survival (CSS) calculated from time of surgery. Results: 55 patients with either clinical pelvic lymph node (PLN) metastasis (n=29) or PLN and RPLN metastasis (n=26) were identified. Median CSS was 19 months for all patients; 21 for PLN alone and 16 for PLN and RPLN disease. Kaplan-Meier estimate of 5-year CSS was 31% with no difference between PLN alone and PLN with RPLN disease. Clinical nodal stage was N1: 16, N2: 5, N3: 8, and M1 (RPLN): 26. Majority (94%) of patients received cisplatinum-based chemotherapy. At cystectomy, all patients underwent a PLN dissection with 12 patients (all clinical M1 RPLN) undergoing concurrent RPLN dissection (RPLND). In all, 30 of 55 (55%) patients were pN0 at the time of surgical extirpation while 26% (5 of 19) were pN+ despite radiologic complete response after chemotherapy. 5-year CSS was 57% for pN0 and 9% for pN+ disease (p<0.0001). Median survival in patients with residual tumor in PLN (n=17) was 10.5 months vs. 7 months for RPLN (n=8) (median survival not reached in pN0 patients, p< 0.001). 17 patients developed recurrences outside the surgical field after a median of 8 months. While no recurrences occurred within the lymphadenectomy template, 14% of patients with clinical M1 RPLN disease who did not undergo RPLND had recurrences in RPLN basin. Conclusions: Post-chemotherapy consolidative surgical resection may result in 5-year disease-free survival in patients with clinical evidence of node-positive disease, including those with RPLN positive disease, who have major response to chemotherapy.

966: Radical Prostatectomy for Lymph Node Positive Prostate Cancer: The M.D. Anderson Cancer Center Experience

2006 ◽  
Vol 175 (4S) ◽  
pp. 311-312
Author(s):  
Philippe E. Spiess ◽  
Joseph E. Busby ◽  
Jennifer Jordan ◽  
Mike Hernandez ◽  
Patricia Troncoso ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Lymph Node ◽  
Radical Prostatectomy ◽  
Cancer Center ◽  
Node Positive ◽  
Lymph Node Positive

Bioinformatic identification of differentially expressed genes associated with prognosis of locally advanced lymph node-positive prostate cancer

2019 ◽  
Vol 17 (01) ◽  
pp. 1950003 ◽  
Author(s):  
Anna V. Kudryavtseva ◽  
Elena N. Lukyanova ◽  
Sergey L. Kharitonov ◽  
Kirill M. Nyushko ◽  
Alexey A. Krasheninnikov ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Lymph Node ◽  
Locally Advanced ◽  
Fusion Transcript ◽  
High Risk Group ◽  
The Cancer Genome Atlas ◽  
Regional Lymph Nodes ◽  
Entire Cohort ◽  
Node Positive ◽  
Lymph Node Positive

Prostate cancer (PCa) is one of the primary causes of cancer-related mortality in men worldwide. Patients with locally advanced PCa with metastases in regional lymph nodes are usually marked as a high-risk group. One of the chief concerns for this group is to make an informed decision about the necessity of conducting adjuvant androgen deprivation therapy after radical surgical treatment. During the oncogenic transformation and progression of the disease, the expression of many genes is altered. Some of these genes can serve as markers for diagnosis, predicting the prognosis or effectiveness of drug therapy, as well as possible therapeutic targets. We undertook bioinformatic analysis of the RNA-seq data deposited in The Cancer Genome Atlas consortium database to identify possible prognostic markers. We compared the groups with favorable and unfavorable prognosis for the cohort of patients with PCa showing lymph node metastasis (pT2N1M0, pT3N1M0, and pT4N1M0) and for the most common molecular type carrying the fusion transcript TMPRSS2-ERG. For the entire cohort, we revealed at least six potential markers (IDO1, UGT2B15, IFNG, MUC6, CXCL11, and GBP1). Most of these genes are involved in the positive regulation of immune response. For the TMPRSS2-ERG subtype, we also identified six genes, the expression of which may be associated with prognosis: TOB1, GALNT7, INAFM1, APELA, RAC3, and NNMT. The identified genes, after additional studies and validation in the extended cohort, could serve as a prognostic marker of locally advanced lymph node-positive PCa.

The role of adjuvant chemotherapy in patients with locally advanced (pT3, pT4a) and/or lymph node–positive bladder cancer

2010 ◽  
Vol 42 (4) ◽  
pp. 959-964 ◽  
Author(s):  
Berkan Reşorlu ◽  
Kadir Türkölmez ◽  
Gül Ergün ◽  
Sümer Baltacı ◽  
Çağatay Göğüş ◽  
...  
Keyword(s):  
Bladder Cancer ◽  
Lymph Node ◽  
Adjuvant Chemotherapy ◽  
Locally Advanced ◽  
Node Positive ◽  
Lymph Node Positive

1150 Adjuvant chemotherapy after radical cystectomy decreases mortality in locally advanced or lymph node positive tumours

2016 ◽  
Vol 15 (3) ◽  
pp. e1150
Author(s):  
M. Fröhner ◽  
R. Koch ◽  
U. Heberling ◽  
V. Novotny ◽  
S. Oehlschlaeger ◽  
...  
Keyword(s):  
Lymph Node ◽  
Adjuvant Chemotherapy ◽  
Radical Cystectomy ◽  
Locally Advanced ◽  
Node Positive ◽  
Lymph Node Positive

Combination of Multiple Molecular Markers Can Improve Prognostication in Patients With Locally Advanced and Lymph Node Positive Bladder Cancer

2010 ◽  
Vol 183 (1) ◽  
pp. 68-75 ◽  
Author(s):  
Shahrokh F. Shariat ◽  
Daher C. Chade ◽  
Pierre I. Karakiewicz ◽  
Raheela Ashfaq ◽  
Hendrik Isbarn ◽  
...  
Keyword(s):  
Bladder Cancer ◽  
Molecular Markers ◽  
Lymph Node ◽  
Locally Advanced ◽  
Node Positive ◽  
Lymph Node Positive
Sign in / Sign up

Export Citation Format

Share Document